284 related articles for article (PubMed ID: 10420109)
1. Topical lomefloxacin 0.3% twice daily versus tobramycin 0.3% in acute bacterial conjunctivitis: A multicenter double-blind phase III study.
Gallenga PE; Lobefalo L; Colangelo L; Della Loggia G; Orzalesi N; Velati P; Bujtar E; Ponte F; Damiani S; Bucci MG; Bonini S; Curatola MR; Palma LA; Bonomi L; Tomazzoli Gerosa L; Pagliarusco A; Milan E; Jauch A
Ophthalmologica; 1999; 213(4):250-7. PubMed ID: 10420109
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of six clinical phase III studies comparing lomefloxacin 0.3% eye drops twice daily to five standard antibiotics in patients with acute bacterial conjunctivitis.
Jauch A; Fsadni M; Gamba G
Graefes Arch Clin Exp Ophthalmol; 1999 Sep; 237(9):705-13. PubMed ID: 10447643
[TBL] [Abstract][Full Text] [Related]
3. Topical lomefloxacin twice daily compared with fucidic acid in acute bacterial conjunctivitis.
Malminiemi K; Kari O; Latvala ML; Voutilainen R; Miettinen A; Jauch A
Acta Ophthalmol Scand; 1996 Jun; 74(3):280-4. PubMed ID: 8828727
[TBL] [Abstract][Full Text] [Related]
4. Microbiological efficacy of 3-day treatment with azithromycin 1.5% eye-drops for purulent bacterial conjunctivitis.
Denis F; Chaumeil C; Goldschmidt P; Delval L; Pouliquen P; Cochereau I; Chainier D; De Barbeyrac B
Eur J Ophthalmol; 2008; 18(6):858-68. PubMed ID: 18988154
[TBL] [Abstract][Full Text] [Related]
5. Treatment of acute bacterial conjunctivitis with topical lomefloxacin 0.3% compared to topical ofloxacin 0.3%.
Tabbara KF; El-Sheikh HF; Islam SM; Hammouda E
Eur J Ophthalmol; 1999; 9(4):269-75. PubMed ID: 10651190
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy assessment of azithromycin 1.5% eye drops versus tobramycin 0.3% on clinical signs of purulent bacterial conjunctivitis].
Robert PY; Bourcier T; Meddeb-Ouertani A; Khairallah M; Zaghloul K; Amraoui A; Bhagat Y; Pop M; Cochereau I
J Fr Ophtalmol; 2010 Apr; 33(4):241-8. PubMed ID: 20223555
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0.3% tobramycin eye drops for bacterial conjunctivitis.
Protzko E; Bowman L; Abelson M; Shapiro A;
Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3425-9. PubMed ID: 17652708
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
Silverstein BE; Allaire C; Bateman KM; Gearinger LS; Morris TW; Comstock TL
Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
[TBL] [Abstract][Full Text] [Related]
9. Treatment of acute bacterial conjunctivitis: 1% fusidic acid viscous drops vs. 0.3% tobramycin drops.
Jackson WB; Low DE; Dattani D; Whitsitt PF; Leeder RG; MacDougall R
Can J Ophthalmol; 2002 Jun; 37(4):228-37; discussion 237. PubMed ID: 12095096
[TBL] [Abstract][Full Text] [Related]
10. A clinical comparison of two formulations of tobramycin 0.3% eyedrops in the treatment of acute bacterial conjunctivitis.
Kernt K; Martinez MA; Bertin D; Stroman D; Cupp G; Martínez C; Tirado M; Guasch J;
Eur J Ophthalmol; 2005; 15(5):541-9. PubMed ID: 16167284
[TBL] [Abstract][Full Text] [Related]
11. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
Karpecki P; Depaolis M; Hunter JA; White EM; Rigel L; Brunner LS; Usner DW; Paterno MR; Comstock TL
Clin Ther; 2009 Mar; 31(3):514-26. PubMed ID: 19393842
[TBL] [Abstract][Full Text] [Related]
12. Microbiological efficacy of a new ophthalmic formulation of moxifloxacin dosed twice-daily for bacterial conjunctivitis.
Tauber S; Cupp G; Garber R; Bartell J; Vohra F; Stroman D
Adv Ther; 2011 Jul; 28(7):566-74. PubMed ID: 21681652
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
McDonald MB; Protzko EE; Brunner LS; Morris TW; Haas W; Paterno MR; Comstock TL; Usner DW
Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients.
Bremond-Gignac D; Mariani-Kurkdjian P; Beresniak A; El Fekih L; Bhagat Y; Pouliquen P; Delval L; Goldschmidt P; Bingen E; Cochereau I
Pediatr Infect Dis J; 2010 Mar; 29(3):222-6. PubMed ID: 19935122
[TBL] [Abstract][Full Text] [Related]
15. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
Schwab IR; Friedlaender M; McCulley J; Lichtenstein SJ; Moran CT;
Ophthalmology; 2003 Mar; 110(3):457-65. PubMed ID: 12623805
[TBL] [Abstract][Full Text] [Related]
16. 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children.
Cochereau I; Meddeb-Ouertani A; Khairallah M; Amraoui A; Zaghloul K; Pop M; Delval L; Pouliquen P; Tandon R; Garg P; Goldschmidt P; Bourcier T
Br J Ophthalmol; 2007 Apr; 91(4):465-9. PubMed ID: 17050578
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of azithromycin 1.5% eye drops in paediatric population with purulent bacterial conjunctivitis.
Bremond-Gignac D; Nezzar H; Bianchi PE; Messaoud R; Lazreg S; Voinea L; Speeg-Schatz C; Hartani D; Kaercher T; Kocyla-Karczmarewicz B; Murta J; Delval L; Renault D; Chiambaretta F;
Br J Ophthalmol; 2014 Jun; 98(6):739-45. PubMed ID: 24526744
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
Comstock TL; Paterno MR; Usner DW; Pichichero ME
Paediatr Drugs; 2010 Apr; 12(2):105-12. PubMed ID: 20218747
[TBL] [Abstract][Full Text] [Related]
19. [Lomefloxacin in treatment of infectious eye diseases].
Maĭchuk IuF; Vakhova ES; Kononenko LA
Antibiot Khimioter; 1998; 43(10):32-5. PubMed ID: 9825108
[TBL] [Abstract][Full Text] [Related]
20. Topical netilmicin compared with tobramycin in the treatment of external ocular infection.
Milazzo G; Papa V; Carstocea B; Chercota G; Rodica P; Gafencu O; Santocono M
Int J Clin Pharmacol Ther; 1999 May; 37(5):243-8. PubMed ID: 10363623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]